Spyre Therapeutics, Inc. (SYRE) shareholders
Close on Nov 18, 2026Market cap $8.95BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Harwin Peter Evan Joint filing with Kiselak Tomas (9.99%), Fairmount Funds Management LLC (9.19%) and 1 more | 10,185,961 | 9.99% | 13D (active) amendment | Oct 7, 2026 |
| Tomas Kiselak Joint filing with Peter Evan Harwin (9.99%), Fairmount Funds Management LLC (9.15%) and 1 more | 9,667,201 | 9.99% | 13D (active) amendment | Jun 23, 2026 |
| Peter Harwin Joint filing with Tomas Kiselak (9.99%), Fairmount Funds Management LLC (9.09%) and 1 more | 9,016,702 | 9.99% | 13D (active) amendment | Apr 16, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (15.00%) | 7,623,881 | 15.00% | 13G (passive) amendment | Nov 12, 2024 |
| Senai Asefaw, M.D. Joint filing with Paradigm BioCapital Advisors LP (5.10%), Paradigm BioCapital Advisors GP LLC (5.10%) | 4,457,450 | 5.10% | 13G (passive) | Sep 24, 2026 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (5.00%), Perceptive Life Sciences Master Fund, Ltd. (5.00%) | 4,319,496 | 5.00% | 13G (passive) | Apr 15, 2026 |
| BlackRock, Inc. | 3,962,635 | 6.60% | 13G (passive) amendment | Jun 30, 2025 |
| RTW Investments, LP Joint filing with Roderick Wong, M.D. (6.20%) | 3,621,996 | 6.20% | 13G (passive) amendment | Dec 31, 2024 |
| Peter E. Deutsch | 3,550,276 | 6.99% | 13G (passive) | Oct 14, 2024 |
| Tang Capital Management, LLC Joint filing with Kevin Tang (5.30%) | 3,200,000 | 5.30% | 13G (passive) | Apr 24, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SYRE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 13,026,187 | 14.77% | $1.16B | +1,245,163 | 0.05% |
| BlackRock, Inc. | 6,506,605 | 7.38% | $577.66M | +985,384 | 0.01% |
| Perceptive Advisors LLC | 4,319,496 | 4.90% | $383.48M | +536,271 | 5.76% |
| Rtw Investments, LP | 4,251,996 | 4.82% | $377.49M | +80,000 | 3.22% |
| Paradigm Biocapital Advisors LP | 3,840,778 | 4.36% | $340.98M | +1,883,512 | 6.38% |
| Vanguard Capital Management LLC | 3,448,681 | 3.91% | $306.17M | +391,280 | 0.01% |
| State Street Corp | 3,057,416 | 3.47% | $271.44M | +450,385 | 0.01% |
| VR Adviser, LLC | 2,985,448 | 3.39% | $265.05M | −700,000 | 8.04% |
| Price T Rowe Associates Inc /Md/ | 2,960,855 | 3.36% | $262.87M | +1,362,125 | 0.03% |
| Driehaus Capital Management LLC | 2,799,166 | 3.17% | $248.51M | +8,381 | 1.44% |
| Geode Capital Management, LLC | 2,562,265 | 2.91% | $239.26M | +841,353 | 0.01% |
| Vanguard Portfolio Management LLC | 2,330,098 | 2.64% | $206.87M | +1,744,968 | 0.01% |
| Capital World Investors | 2,315,553 | 2.63% | $205.57M | +1,648,989 | 0.02% |
| Jupiter Topco LLC | 2,206,936 | 2.50% | $195.88M | New | 0.08% |
| TCG Crossover Management, LLC | 1,900,582 | 2.16% | $168.73M | – | 4.06% |
| Tang Capital Management LLC | 1,892,200 | 2.15% | $167.99M | – | 7.63% |
| Bank Of America Corp /De/ | 1,777,854 | 2.02% | $157.84M | +549,761 | 0.01% |
| Adage Capital Partners Gp, L.L.C. | 1,722,300 | 1.95% | $152.91M | New | 0.21% |
| Wellington Management Group Llp | 1,581,505 | 1.79% | $140.41M | −243,306 | 0.02% |
| Goldman Sachs Group Inc | 1,478,059 | 1.68% | $131.22M | +1,208,121 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 265 | 96M | 100.0% | 91 / 104 | 56 / 21 | 27M | 12M |
| Q1 2026 | 198 | 83M | 94.0% | 58 / 67 | 49 / 11 | 12M | 7M |
| Q4 2025 | 153 | 81M | 91.8% | 30 / 76 | 27 / 14 | 23M | 6M |
| Q3 2025 | 137 | 65M | 73.2% | 22 / 44 | 43 / 13 | 5M | 4M |
| Q2 2025 | 129 | 64M | 72.2% | 18 / 63 | 26 / 17 | 6M | 4M |
| Q1 2025 | 129 | 62M | 70.4% | 20 / 53 | 34 / 21 | 7M | 5M |
| Q4 2024 | 131 | 60M | 67.9% | 34 / 62 | 21 / 21 | 13M | 5M |
| Q3 2024 | 119 | 51M | 58.3% | 31 / 42 | 24 / 18 | 10M | 7M |
| Q2 2024 | 107 | 51M | 57.8% | 29 / 47 | 17 / 23 | 21M | 2M |
| Q1 2024 | 102 | 32M | 36.0% | 54 / 20 | 15 / 6 | 9M | 5M |
| Q4 2023 | 54 | 28M | 31.8% | 30 / 16 | 4 / 3 | 25M | 0M |
| Q3 2023 | 27 | 3M | 3.7% | 27 / 0 | 0 / 0 | 3M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
280 funds held SYRE in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SYRE | Value | % of fund | As of |
|---|---|---|---|---|---|
| SMALLCAP World Fund Inc | 2,780,536 | 3.15% | $246.86M | 0.26% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,576,969 | 2.92% | $189.41M | 0.19% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,482,298 | 2.82% | $220.38M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,911,678 | 2.17% | $169.72M | 0.20% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,326,035 | 1.50% | $117.73M | 1.10% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 896,559 | 1.02% | $79.60M | 0.04% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 886,177 | 1.01% | $78.67M | 0.08% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 857,347 | 0.97% | $84.30M | 3.83% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 814,290 | 0.92% | $80.07M | 0.24% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 777,720 | 0.88% | $76.47M | 0.87% | Jul 31, 2026 |
| Select Health Care Portfolio | 760,000 | 0.86% | $55.86M | 0.97% | May 31, 2026 |
| Fidelity Growth Company K6 Fund | 749,630 | 0.85% | $55.10M | 0.20% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 711,845 | 0.81% | $63.20M | 0.53% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 687,511 | 0.78% | $61.04M | 0.40% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 673,799 | 0.76% | $59.82M | 0.41% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Cameron Turtle | Chief Executive Officer, Director | 537,540 | 0.61% | Oct 2, 2026 |
| Scott L. Burrows | Chief Financial Officer | 79,762 | 0.09% | Oct 2, 2026 |
| Heidy King-Jones | See Remarks | 2,845 | 0.00% | Oct 2, 2026 |
| Sheldon Sloan | Chief Medical Officer | 8,334 | 0.01% | Jul 2, 2026 |
| Jeffrey W. Albers | Director | 9,360 | 0.01% | Aug 10, 2026 |
| Michael Thomas Henderson | Director | 68,606 | 0.08% | Jun 23, 2026 |
| Healthcare Fund II L.P. Fairmount | Director | 1,190,497 | 1.35% | Jun 23, 2026 |
| Tomas Kiselak | Director | 9,460,540 | 10.73% | Jun 23, 2026 |
| Funds Management LLC Fairmount | Director | 812,076 | 0.92% | Jun 23, 2026 |
| Peter Evan Harwin | Director | 4,830,177 | 5.48% | Jun 23, 2026 |
| Mark C. McKenna | Director | – | – | May 29, 2026 |
| Laurie Stelzer | Director | – | – | May 29, 2026 |
| Sandra Milligan | Director | – | – | May 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Heidy King-Jones See Remarks | Oct 1, 2026 | Sale(10b5-1 plan) | −2,600 | $93.46 | $243.00K | 2,845 |
| Heidy King-Jones See Remarks | Oct 1, 2026 | Sale(10b5-1 plan) | −2,100 | $92.70 | $194.67K | 5,445 |
| Heidy King-Jones See Remarks | Oct 1, 2026 | Sale(10b5-1 plan) | −7,228 | $91.35 | $660.28K | 7,545 |
| Heidy King-Jones See Remarks | Oct 1, 2026 | Sale(10b5-1 plan) | −16,605 | $90.35 | $1.50M | 14,773 |
| Heidy King-Jones See Remarks | Oct 1, 2026 | Sale(10b5-1 plan) | −400 | $89.24 | $35.70K | 31,378 |
| Heidy King-Jones See Remarks | Oct 1, 2026 | Option exercise | +28,933 | $14.50 | $419.53K | 31,778 |
| Cameron Turtle Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −100 | $93.91 | $9.39K | 537,540 |
| Cameron Turtle Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −4,990 | $93.37 | $465.92K | 537,640 |
| Cameron Turtle Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −3,989 | $92.31 | $368.22K | 542,630 |
| Cameron Turtle Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −2,638 | $91.49 | $241.35K | 546,619 |
| Cameron Turtle Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −2,683 | $90.10 | $241.74K | 549,257 |
| Cameron Turtle Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −600 | $89.14 | $53.48K | 551,940 |
| Scott L. Burrows Chief Financial Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −229 | $93.57 | $21.43K | 79,762 |
| Scott L. Burrows Chief Financial Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −3,071 | $92.95 | $285.45K | 79,991 |
| Scott L. Burrows Chief Financial Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −2,100 | $91.92 | $193.03K | 83,062 |
| Scott L. Burrows Chief Financial Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −1,500 | $90.27 | $135.41K | 85,162 |
| Scott L. Burrows Chief Financial Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −600 | $89.07 | $53.44K | 86,662 |
| Scott L. Burrows Chief Financial Officer | Oct 1, 2026 | Option exercise | +7,500 | $14.50 | $108.75K | 87,262 |
| Scott L. Burrows Chief Financial Officer | Sep 30, 2026 | Sale(10b5-1 plan) | −17,500 | $89.89 | $1.57M | 79,762 |
| Scott L. Burrows Chief Financial Officer | Sep 30, 2026 | Option exercise | +17,500 | $14.50 | $253.75K | 97,262 |
| Heidy King-Jones See Remarks | Sep 2, 2026 | Option exercise | +400 | $14.50 | $5.80K | 3,245 |
| Heidy King-Jones See Remarks | Sep 2, 2026 | Sale(10b5-1 plan) | −400 | $90.00 | $36.00K | 2,845 |
| Scott L. Burrows Chief Financial Officer | Sep 2, 2026 | Sale(10b5-1 plan) | −18,232 | $89.35 | $1.63M | 79,762 |
| Heidy King-Jones See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −400 | $89.38 | $35.75K | 2,845 |
| Heidy King-Jones See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −6,206 | $88.17 | $547.18K | 3,245 |
| Heidy King-Jones See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −16,548 | $87.20 | $1.44M | 9,451 |
| Heidy King-Jones See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −4,845 | $86.40 | $418.61K | 25,999 |
| Heidy King-Jones See Remarks | Sep 1, 2026 | Option exercise | +27,999 | $14.50 | $405.99K | 30,844 |
| Cameron Turtle Chief Executive Officer, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −3,700 | $88.06 | $325.82K | 552,940 |
| Cameron Turtle Chief Executive Officer, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −400 | $89.07 | $35.63K | 552,540 |
| Cameron Turtle Chief Executive Officer, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −2,500 | $86.36 | $215.90K | 565,040 |
| Cameron Turtle Chief Executive Officer, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −8,400 | $87.15 | $732.06K | 556,640 |
| Scott L. Burrows Chief Financial Officer | Sep 1, 2026 | Option exercise | +7,500 | $14.50 | $108.75K | 105,494 |
| Scott L. Burrows Chief Financial Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −4,384 | $87.11 | $381.89K | 100,210 |
| Scott L. Burrows Chief Financial Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −900 | $86.25 | $77.63K | 104,594 |
| Scott L. Burrows Chief Financial Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −2,016 | $88.03 | $177.47K | 98,194 |
| Scott L. Burrows Chief Financial Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −200 | $89.04 | $17.81K | 97,994 |
| Jeffrey W. Albers Director | Aug 7, 2026 | Sale(10b5-1 plan) | −10,000 | $104.68 | $1.05M | 9,360 |
| Jeffrey W. Albers Director | Aug 7, 2026 | Sale(10b5-1 plan) | −8,000 | $104.38 | $835.04K | 19,360 |
| Jeffrey W. Albers Director | Aug 7, 2026 | Sale(10b5-1 plan) | −5,000 | $104.47 | $522.35K | 0 |
| Jeffrey W. Albers Director | Aug 7, 2026 | Option exercise | +5,000 | $10.39 | $51.95K | 5,000 |
| Cameron Turtle Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −16 | $97.46 | $1.56K | 567,540 |
| Cameron Turtle Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −1,392 | $96.82 | $134.77K | 567,556 |
| Cameron Turtle Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −5,635 | $95.93 | $540.57K | 568,948 |
| Cameron Turtle Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −7,157 | $95.10 | $680.63K | 574,583 |
| Cameron Turtle Chief Executive Officer, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −800 | $93.97 | $75.18K | 581,740 |
| Scott L. Burrows Chief Financial Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −100 | $97.10 | $9.71K | 97,994 |
| Scott L. Burrows Chief Financial Officer | Aug 3, 2026 | Option exercise | +7,500 | $14.50 | $108.75K | 105,494 |
| Scott L. Burrows Chief Financial Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −5,100 | $95.21 | $485.57K | 100,394 |
| Scott L. Burrows Chief Financial Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −2,300 | $96.30 | $221.49K | 98,094 |
| Sheldon Sloan Chief Medical Officer | Jul 1, 2026 | Option exercise | +8,334 | $27.46 | $228.85K | 8,334 |
| Sheldon Sloan Chief Medical Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −6,500 | $87.52 | $568.88K | 1,834 |
| Sheldon Sloan Chief Medical Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −1,834 | $88.34 | $162.02K | 0 |
| Scott L. Burrows Chief Financial Officer | Jul 1, 2026 | Option exercise | +7,500 | $14.50 | $108.75K | 105,494 |
| Scott L. Burrows Chief Financial Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −1,725 | $88.37 | $152.44K | 97,994 |
| Scott L. Burrows Chief Financial Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −5,775 | $87.55 | $505.60K | 99,719 |
| Cameron Turtle Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −10,176 | $87.44 | $889.79K | 587,364 |
| Cameron Turtle Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −590 | $88.91 | $52.46K | 582,540 |
| Cameron Turtle Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −4,234 | $88.12 | $373.10K | 583,130 |
| Scott L. Burrows Chief Financial Officer | Jun 25, 2026 | Option exercise | +15,000 | $14.50 | $217.50K | 112,994 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Spyre Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 24,790 shares on Sep 10, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Heidy King-Jones Officer | Oct 1, 2026 | 29,335 | $2.61M | Oct 1, 2026 | Exercise of Stock Options |
| Cameron Turtle Director, Officer | Oct 1, 2026 | 45,000 | $4.01M | Oct 1, 2026 | Previously Exercised Stock Options |
| Scott L. Burrows Officer | Sep 30, 2026 | 17,500 | $1.57M | Sep 30, 2026 | Stock Option Exercise |
| Heidy King-Jones Officer | Sep 1, 2026 | 46,665 | $4.17M | Sep 1, 2026 | Exercise of Stock Options |
| Jeffrey W. Albers Director | Aug 7, 2026 | 5,000 | $517.10K | Aug 7, 2026 | Exercise of Stock Options |
| Sessions, LLC Director | Aug 7, 2026 | 18,000 | $1.86M | Aug 7, 2026 | Open Market Purchase |
| Scott L. Burrows Officer | Aug 3, 2026 | 30,000 | $2.95M | Aug 3, 2026 | Exercise of Stock Options |
| Cameron Turtle Director, Officer | Jul 1, 2026 | 45,000 | $4.00M | Jul 1, 2026 | Previously Exercised Stock Options |
| Scott L. Burrows Officer | Jun 25, 2026 | 15,000 | $1.31M | Jun 25, 2026 | Stock Option Exercise |
| Healthcare Fund II L.P. Fairmount Director | Jun 23, 2026 | 4,684,781 | $399.66M | Jun 23, 2026 | Acquired in reverse merger transaction |
| Michael Thomas Henderson Director | Jun 22, 2026 | 20,000 | $1.77M | Jun 22, 2026 | Restricted Stock Units |
| Sheldon Sloan Officer | Jun 3, 2026 | 16,667 | $1.15M | Jun 3, 2026 | Exercise of Stock Options |
| Michael Thomas Henderson Director | May 8, 2026 | 80,000 | $5.85M | May 8, 2026 | Restricted Stock Units |
| Scott L. Burrows Officer | May 1, 2026 | 27,500 | $2.05M | May 1, 2026 | Exercise of Stock Options |
| Sheldon Sloan Officer | May 1, 2026 | 78,333 | $5.83M | May 1, 2026 | Exercise of Stock Options |
See a number that looks wrong?